Eisai Co., Ltd. announced that the European Medicines Agency has accepted for evaluation a marketing authorization application for its in-house-discovered and developed orexin receptor antagonist lemborexant for the… read more.
NICE (UK): Cemiplimab can be used as an option to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults if: i)… read more.
Eton Pharmaceuticals, Inc announced that the Company’s new formulation of Khindivi (hydrocortisone) oral solution successfully showed bioequivalence to Alkindi Sprinkle (hydrocortisone) oral granules, the FDA-approved hydrocortisone granule formulation,… read more.
Sanofi withdrew its application for the use of Dupixent (dupilumab) in the treatment of adults with moderate-to-severe bullous pemphigoid, an autoimmune skin disease causing widespread itching and blisters… read more.
Pfizer announced that the FDA accepted for Priority Review a supplemental New Drug Application (sNDA) for Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with… read more.
Organon will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the efficacy and safety… read more.
NICE(UK): Pembrolizumab with chemoradiotherapy (external beam radiation therapy followed by brachytherapy) can be used, within its marketing authorisation, as an option for untreated International Federation of Gynecology and… read more.
NICE (UK): Deuruxolitinib can be used, within its marketing authorisation, as an option to treat severe alopecia areata in adults. Deuruxolitinib can only be used if the company… read more.
According to the MHRA website, the MHRA approved Retifanlimab (Zynyz) as the first treatment given to adults with advanced Merkel cell skin cancer that has spread or returned… read more.
Amneal Pharmaceuticals announced that it has received FDA approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100… read more.
Shionogi & Co announced the FDA has accepted a Supplemental New Drug Application (sNDA) for Fetroja (cefiderocol) for the treatment of pediatric patients (at least 26 weeks of… read more.
Novo Nordisk announced that the European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
